Our team

Devrim Aran has extensive experience in pharmaceutical and biotech. Previously lead R&D, regulatory, and global business strategy of small molecules in complex chronic diseases at Innox Corp as CEO and GPL (Global Project Leader). Devrim Aran was the CEO of Arkhe Pharmaceuticals Corp where he led R&D, manufacture and global business strategy of biologics, biosimilars, novel inhalation products and injectable generics.  Devrim Aran was the Head of US Commercialization for top onc/hem products at Novartis with more than $ 1 Billion in revenue. He was also a member of Novartis GDP (Global Development Project) team in IDTI (Infectious Disease, Transplant and Immunology) business unit. Prior to that, Devrim Aran was the Head of Business Solutions at Abraxis Oncology / APP where he was responsible for pricing, contracting, reimbursement, account management and commercialization of Abraxane (nabpaclitaxel) in solid tumors and ultimately drove $ 135 M net sales in 9 months at launch with the help of pricing and contracting strategies.  Devrim Aran was the Head of Marketing at Roche Laboratories where he was ultimately responsible for the turnaround of Kytril (granisetron) in CINV / RINV (chemo and radiation induced nausea and vomiting) and the launch in PONV (postoperative nausea and vomiting).

Mr. Robert Niziol – has more than 25 years of experience in capital markets, Venture Capital, Private Equity, management, and business consulting. Since 2005 Robert is a Partner at Penton Partners, a private equity fund investing in lower middle-market private companies in Poland. Previously Robert worked in the Credit Derivatives and Structured Credit Products Group at JPMorgan Chase. He founded several companies, including Pin4 Cardless Cash (now MasterCard Cash Pick Up), Invex Ionics and Axen Bio Group. Robert advised many SMEs, large corporations and governmental agencies on various business-related matters, including restructuring, turnarounds, business development, and capital structures. Robert spoke at many international conferences related to Private Equity and Venture Capital. Robert holds a BA in International Business and Finance from Anisfield School of Business (Ramapo College of NJ). He completed the Management and Leadership Executive Education programs at Harvard Business School and the London Business School of Economics.